Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

WHITE PLAINS, N.Y., Feb. 19, 2013 /PRNewswire/ -- In 1964, the five-year survival rate for the most common form of childhood leukemia was only three percent but, today, thanks to treatment advances, about 90 percent of children survive. As the leading global non-profit organization dedicated to curing blood cancers, The Leukemia & Lymphoma Society (LLS) has invested nearly one billion dollars in blood cancer research since 1954, bringing us closer than ever to realizing a world without blood cancers.

(Photo:  http://photos.prnewswire.com/prnh/20130219/NY61444 )

LLS has achieved its leadership position through a unique approach to research and fundraising. Its venture philanthropy model forges partnerships with pharmaceutical and biotechnology companies, academia, medical centers and the National Institutes of Health, to foster the process of drug discovery from basic research to translational and clinical research. Rather than duplicate what the federal government is funding, LLS developed its own research agenda to accelerate the development of promising new life-saving therapies with a focus on un-met medical need.

"We're not your grandfather's charity," proclaims Louis DeGennaro , PhD, LLS chief mission officer. "There is no means of preventing or early screening for blood cancers, so our focus is on life-saving research to find cures. LLS research funding has touched the discovery or development of nearly every therapy used in the battle against blood cancers – including targeted drugs, like Gleevec®, Velcade® and Kyprolis™, and immunotherapies, like Rituxan®."

In fact, LLS is playing a unique role in the pathway to cures, especially for a non-profit organization.  Blood cancers, which include leukemia, lymphoma, myeloma and myelodysplastic syndromes, are hema
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... (PRWEB) May 22, 2015 Knowledgent ... white paper that explores the potential of big data ... white paper was developed to help life sciences and ... leverage data to gain critical business insights. , The ... amounts of data driven by patient profiling, compliance and ...
(Date:5/21/2015)... NEW YORK , May 21, 2015 /PRNewswire/ ... Prader-Willi Research (FPWR), a nonprofit organization dedicated to ... of Prader-Willi syndrome (PWS), announced today that FPWR ... Leon and Irina Shaulov contributed $1 ... and clinical initiatives.  ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... from the medical community in Europe and the U.S. examined ... disease and sepsis, and in cardiac surgery, during CSL ... in Clinical Fluid Management ." (Logo: ... frank and provocative exchange about the uses and effectiveness of ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ) ... of Pathology & Laboratory Medicine, University of Pennsylvania, and ... been elected a fellow in the American Association for ... the "father of synthetic DNA vaccines," is being honored ...
... Researchers at Northwestern University have developed a new ... could be a step toward the creation of ... its many promising attributes, graphene is a one-atom ... strength and conductivity. Among graphene,s many possible applications ...
Cached Biology Technology:Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 2Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 3Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 2Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 3Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 4A step toward better electronics 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... CORVALLIS, Ore. Researchers at Oregon State University for the ... overfishing and nitrate pollution can help destroy coral reefs ... bring with it unwanted pathogens, choke off oxygen and disrupt ... big enough to essentially smother corals. They can get out ...
... who take the time to read food labels are ... from a recently released study authored by Steven T. ... of Agriculture,s Department of Agricultural and Resource Economics, in ... Compostela in Spain, the University of Arkansas and the ...
... press release is available in Spanish . ... Development, NEIKER-Tecnalia, and the National Institute of Agricultural Research in ... of ,black dead arm, (BDA) on grapevine leaves are, in ... and BDA are diseases that affect the trunk of ...
Cached Biology News:The 'slippery slope to slime': Overgrown algae causing coral reef declines 2NEIKER and INRA discover that BDA symptoms in grapevine leaves are a sign of esca 2
...
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... acids 178-227 of human YBX2. ... is proprietary). ...
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Biology Products: